AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06188026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinylestradiol/levonorgestrel
Description: Oral contraceptive is taken as tablet daily composed of 30 μg ethinylestradiol and 150 μg levonorgestrel.
Study NCT06176742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Cycle Breathing Technique
Description: This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group A will be treated with ACBT. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
Study NCT06176742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bubble Positive Expiratory Pressure Device
Description: This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group B will be treated with bubble-PEP. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
Study NCT01078610 — intervention group
Intervention type: BIOLOGICAL
Intervention: adalimumab (Humira)
Description: 40 mg adalimumab (Humira) every other week.
Study NCT05217940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic tests for anal cancer screening
Description: The initial screening interventions will include the collection of (1) anal cytology; (2) self-collected HPV testing specimens (by subjects); (3) a clinician collected HPV specimen. A digital rectal exam will also be done on all patients.
Study NCT04928625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904
Description: SHR-A1904
Study NCT06415552 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-Based Stress Reduction
Description: Eight iterations of the MBSR course will be delivered, over a total period of 24 months. Each iteration will take place over 8 weeks. Courses would consist of 8 weekly sessions, led by certified mindfulness instructors. Sessions will include core meditation practices, psychoeducation, and home practices.
Study NCT05522777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drink one bottle of Yakult a day
Description: Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota
Study NCT05666193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT Imaging
Description: Subjects are scheduled for two imaging sessions on the Ethos system with the HyperSight CBCT. One session is on the same day as the CT simulation scan for treatment planning. The second session is on the same day as the delivery of ther 21st treatment fraction. If the subject is sent for a mid-treatment FBCT for re-planning, a third HyperSight CBCT imaging session will be scheduled on the same day as the mid-treatment FBCT.
Study NCT05278975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSO-021
Description: A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
Study NCT04219046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxégol oxalate
Description: Oral administration once daily
Study NCT04219046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Oral administration once daily
Study NCT05582655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONLINE
Description: The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
Study NCT05582655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH
Description: COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, \& Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, \& Arbuckle, 2021).
Study NCT05419635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asundexian (BAY2433334)
Description: Study intervention BAY2433334 will be administered as tablet taken orally.
Study NCT04809532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse abdominis plane (TAP) block
Description: Ultrasound guide bilateral TAP block at end of cesarean section
Study NCT04809532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 20ml 0.25% bupvicaine
Study NCT04809532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: intravenous tramadol
Study NCT05148221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Once each participant signs an informed consent form upon agreeing to participate in the study, they will be asked to complete a simple demographic questionnaire including year in program, work schedule, self-reported height and weight, age, and sex. They will also be interviewed by a faculty of university of Wisconsin-Eau Claire (UWEC) regarding their current and past exercise habits, exercise preferences, and perceived exercise barriers. Two questionnaires listed above (Occupational Fatigue Exhaustion Recovery (OFER 15) and Maslach Burnout Inventory (MBI)) will also be completed by each participant on Qualtrics online platform.
Study NCT05148221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actigraph and activPAL devices
Description: Actigraph and activPAL devices will be set up based on the demographic information and will be provided to each participant to wear for 7 consecutive days during all waking hours and sleep, except when bathing or swimming. If the first 7-day monitoring period was an overnight inpatient week, the second 7-day monitoring period will be scheduled during a non-overnight week. A day before the first day of the second monitoring period, a new set of Actigraph and activPAL devices will be delivered to each participant. Once the second monitoring period ends, devices will be retrieved from each participant, and data will be downloaded from devices.
Study NCT05032300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focused shockwave
Description: Procedure: Focused shockwave therapy received shock wave therapy once a week: first locate, touch on the heel of the patient Tenderness points, take tenderness points as treatment points;Then ask the patient to take the lower limbs straight sitting or prone position, Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, Total of 3000 pulses; rest for 20 minutes after the treatment
Study NCT05032300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home therapy
Description: Stretching and ice massage
Study NCT06098937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalifilcon Toric Lens
Description: Kalifilcon A Daily Disposable Toric for Ametropia
Study NCT04961944 — intervention group
Intervention type: OTHER
Intervention: Disease assessment
Description: A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested.
Study NCT06098937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total1 for Astigmatism
Description: Total1 for Astigmatism
Study NCT06098937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision1 for Astigmatism
Description: Precision1 for Astigmatism
Study NCT06098937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyDay Toric
Description: MyDay Toric
Study NCT06222580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06222580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT06222580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO
Study NCT06222580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given PO
Study NCT05616481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Burch colposuspension
Description: The original Burch procedure will be performed
Study NCT05616481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modefied Burch (TOT - like)
Description: more lateral fixation to avoid post-operative voiding dysfunction
Study NCT06183580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurofeedback training involving dACC
Description: Participants are pseudorandomized to the dACC group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the dACC. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase dACC neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity > baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed.
Study NCT06183580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurofeedback training involving amygdala
Description: Participants are pseudorandomized to the rAMY group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the rAMY. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase rAMY neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity > baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed.
Study NCT06406049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will receive the standard of care (beginning of the study) which includes sexual health information once in-person for up to 15 minutes for the duration of the study.
Study NCT06406049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network intervention
Description: Participants will come to the study location for up to 2 hours three times (beginning of the study, 6-month and 12-month follow-ups) during the duration of the study. During the study, participants will receive sexual health counseling for HIV prevention. Additionally participants will receive information and resources for PrEP usage. Participants will be encouraged to share sexual health information two times (three and nine months after the beginning of the study) during the duration of the study.
Study NCT05579964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hcl 100 Mcg/mL Inj
Description: Priming dose of 0.5 mcg/kg in a 5 ml syringe mixed in priming fluid and 0.25 mcg/kg/hour DEX infusion diluted in 0.9% NaCl 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
Study NCT05579964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
Study NCT04553159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived stem cells
Description: Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
Study NCT04553159 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous adipose derived stem cells
Description: Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
Study NCT05775887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UQSC2 Vaccine
Description: Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.
Study NCT05775887 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NVX-CoV2373 vaccine
Description: Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
Study NCT04952181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical biometry
Description: optical biometry is a fast, noncontact method it uses the method of partial coherence interferometry (PCI) to measure the axial length (AXL), based on reflection of the interference signal of the retinal pigment epithelium.
Study NCT04952181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic biometry
Description: ultrasonic biometry is contact method depends on ultrasonic transducer producing thin sound beam travelling through different media of the eye when it faces interface of substance dissimilar from that it is travelling through part is reflecting and the other travel through the different substance
Study NCT05111782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Modulation Approach, Movement Control Approach, Functional Optimization Approach
Description: Based on the patients' symptoms and level of disability, either symptom modulation or movement control or functional optimization exercises will be used. The exercises will be provided on alternate days for a duration of 30 minutes in each session preceded by electrotherapeutic modalities for pain relief and muscle relaxation. These modalities will be given for 15 min in each session. The total no. of sessions will be based on the patient's progress for a maximum of 4 weeks.
Study NCT04854161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic Attunement to Affect Training
Description: Empathic Attunement to Affect:~Empathy and neuroscience Therapeutic Presence~Opening receptivity channels Empathic reflections and landscapes (external, meaning and feeling)~Types of emotions: Primary (adaptive, maladaptive), Secondary. Emotion Scheme Types of experiential responses: conjectures, exploration.~Working with Core emotions Types of experiential responses: Evocation and Empathic affirmation,~Empathy and Emotion Productivity Types of experiential responses: Empathic formulation, process suggestion Difficult situations: working on assertive anger and self-soothing Types of experiential responses: Facilitative Congruence
Study NCT04854161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empathic Attunement to Affect Training
Description: Empathic Attunement to Affect:~Empathy and neuroscience Therapeutic Presence~Opening receptivity channels Empathic reflections and landscapes (external, meaning and feeling)~Types of emotions: Primary (adaptive, maladaptive), Secondary. Emotion Scheme Types of experiential responses: conjectures, exploration.~Working with Core emotions Types of experiential responses: Evocation and Empathic affirmation,~Empathy and Emotion Productivity Types of experiential responses: Empathic formulation, process suggestion Difficult situations: working on assertive anger and self-soothing Types of experiential responses: Facilitative Congruence
Study NCT04854161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Training
Description: Compassion Training Introduction to Mindfulness Compassion toward a significant other Compassion toward a generic other Self-compassion Tonglen Compassion toward a difficult other
Study NCT04854161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focusing Oriented Therapy Training
Description: Focusing-Oriented Therapy training Introduction to focusing Acceptance and empathy as the main focusing attitudes Fels-sense markers Felt sense, handle and resonance Hakomi Therapy The Safe Place. Focusing with a challenging person
Study NCT05725239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessions will be identical to TMS treatment sessions and will have the same 30 minute break between each treatment session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active.
Study NCT05725239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Participants will receive 20 trains of 30 pulses each for a total of 600 pulses per session. We will repeat this for 6 sessions each day, with at least 30 minutes between each session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active, so participants will get 24 TMS sessions over the course.
Study NCT05186974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered intravenously
Study NCT06211101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing training on kangaroo care guide
Description: Online training was given to neonatal nurses on the kangaroo care guide created by the researcher in line with the literature.
Study NCT05186974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously
Study NCT05186974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously
Study NCT05186974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously
Study NCT06695910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monoglyceride Eicosapentaenoic acid (omega-3)
Description: 515 mg MAG-EPA + 33 mg MAG-DHA per capsule x 3 capsules daily: 1.5g/day (MAG-EPA). Subjects will be treated over a period of 56 days followed by a wash-out period of 28 days.
Study NCT06695910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Description: 698 mg sunflower oil per capsule x 3 capsules: 2.0g/d sunflower oil (Placebo) Subjects will be treated over a period of 56 days followed by a wash-out period of 28 days.
Study NCT04633187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals.
Study NCT04633187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
Study NCT05728359 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Blood sampling and clinical data collection
Study NCT05108428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.